Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Gamifant

PharmaCompass

01

Brand Name : Gamifant

Emapalumab

arrow
American Pharma Summit
Not Confirmed

Brand Name : Gamifant

arrow
American Pharma Summit
Not Confirmed

Emapalumab

Main Therapeutic Indication : Immunology

Currency : USD

2019 Revenue in Millions : 54

2018 Revenue in Millions : 0

Growth (%) : New launch

blank

02

Brand Name : Gamifant

Emapalumab

arrow
American Pharma Summit
Not Confirmed

Brand Name : Gamifant

arrow
American Pharma Summit
Not Confirmed

Emapalumab

Main Therapeutic Indication : Immunology

Currency : USD

2020 Revenue in Millions : 73

2019 Revenue in Millions : 65

Growth (%) : 12

blank

03

Brand Name : Gamifant

Emapalumab

arrow
American Pharma Summit
Not Confirmed

Brand Name : Gamifant

arrow
American Pharma Summit
Not Confirmed

Emapalumab

Main Therapeutic Indication : Immunology

Currency : USD

2021 Revenue in Millions : 90

2020 Revenue in Millions : 67

Growth (%) : 38

blank

04

Brand Name : Gamifant

Emapalumab

arrow
American Pharma Summit
Not Confirmed

Brand Name : Gamifant

arrow
American Pharma Summit
Not Confirmed

Emapalumab

Main Therapeutic Indication : Immunology

Currency : USD

2022 Revenue in Millions : 84

2021 Revenue in Millions : 90

Growth (%) : -7

blank

05

Brand Name : Gamifant

Emapalumab

arrow
American Pharma Summit
Not Confirmed

Brand Name : Gamifant

arrow
American Pharma Summit
Not Confirmed

Emapalumab

Main Therapeutic Indication : Rare Diseases

Currency : USD

2023 Revenue in Millions : 158

2022 Revenue in Millions : 84

Growth (%) : 84

blank